INTRODUCTION
Prostate cancer (PCa) is one of the most commonly diagnosed solid organ malignancies worldwide, and its incidence is increasing gradually. PCa is a heterogeneous disease that varies in spectrum from tumors with a low risk of mortality to highly aggressive malignant disease. 1 Several primary treatment modalities have been established, including radical prostatectomy, androgen deprivation therapy, and radiation therapy. Of these, radical prostatectomy is the gold-standard definitive therapy for patients with localized PCa. Recently, laparoscopic radical prostatectomy and robotic radical prostatectomy have become popular. 2 However, approximately 25% of males with PCa will develop a postoperative biochemical recurrence (BCR) within 5 years of a radical prostatectomy, and the 10-year risk of BCR is approximately 35%. 3, 4 The prognosis after radical prostatectomy is generally based on clinical findings (preoperative prostate-specific antigen [PSA] level and PSA doubling time) and pathological findings (the Gleason score, surgical margin status, extra-prostatic extension, and seminal vesicle invasion). 4, 5 Using hospital records, we assessed the following potential predictors of a PCa prognosis: patient age, preoperative PSA, preoperative serum testosterone, preoperative PSA density (PSAD), prostate volume, presence of hypoechoic lesion on TRUS, Gleason score (GS), positive core percentage of the TRUS biopsy, clinical stage, pathological stage, postoperative Gleason score, positive surgical margin, perineural invasion, lymphovascular invasion, EPE, BCR, and D' Amico risk classification. Prostate volume was calculated from the TRUS at the time of prostate biopsy using the formula V = 0.52 (length × width × height), 8 and PSAD was obtained by dividing the serum PSA level by the prostate volume. BCR was defined as two consecutive increases in the postoperative PSA >0.2 ng ml −1 . The D' Amico risk was classified as low (PSA < 10, cT1-T2a stage and GS ≤6), intermediate (PSA 10-20 and cT2b stage or GS 7), or high (PSA >20 or cT2c-T3a stage or GS 8-10).
9
Measuring preoperative serum testosterone Using an immunoassay, the preoperative serum testosterone was measured in the morning when testosterone levels are high and stable. Based on a median preoperative testosterone level of 3 ng ml −1 , the patients were categorized into two groups: serum testosterone <3 ng ml −1 (hypogonadism) and preoperative serum testosterone ≥3 ng ml −1 (normal). 7 The candidate predictors of the prognosis of PC listed above were compared between two groups.
Measuring the percent tumor volume
The LRP specimens were fixed in formalin, inked, sectioned serially at 3-mm intervals in a plane perpendicular to the rectal surface, and embedded in paraffin. Then, the specimens were cut to thicknesses of 5 µm and examined microscopically. One uropathologist (C Choi) examined the slides without knowledge of the patient outcomes. The tumor area was marked on each glass slide, the diameter was measured, and the volume of tumor was calculated. PTV was determined as the sum of all visually estimated tumor foci in every section. A positive surgical margin was defined as tumor cells on the inked surface of the specimen.
Statistics
Statistical analyses were performed using SPSS version 17.0 (SPSS, Chicago, IL, USA). The Student's t-test and Chi-square test were used to compare baseline clinicopathological characteristics. Univariate and multivariate (stepwise forward procedure) logistic regression analyses were performed to generated an adjusted odds ratio (OR), representing the independent predictive factors. Statistical significance was set at P < 0.05 for all analyses.
RESULTS

Clinicopathological characteristics
The clinicopathological characteristics of the normal and hypogonadal patients are summarized in , OR, 10.6; 95% CI, 6.57-17.2, P = 0.001), clinical stage (≥ T3, OR, 2.11; 95% CI, 1.24-3.58, P = 0.005), TRUS biopsy Gleason score (7-10, OR, 2.83; 95% CI, 1.86-4.31, P = 0.001), and D' Amico classification (high, OR, 3.22; 95% CI, 2.13-4.89, P = 0.001) were associated with EPE, whereas age (≥69), prostate volume, and the presence of a hypoechoic lesion on TRUS were not associated with EPE ( Table 2) .
The multivariate analysis revealed that the preoperative serum PSA (adjusted OR, 1.04, 95% CI, 1.02-1.06, P = 0.001), TRUS biopsy positive core percentage (adjusted OR, 1.01; 95% CI, 1.00-1.03, P = 0.001), and preoperative serum testosterone (<3 ng ml −1 , adjusted OR, 8.52; 95% CI, 5.04-14.4, P = 0.001) were associated with EPE ( Table 2) .
Predictors of biochemical recurrence
The univariate analyses indicated that the preoperative serum PSA (OR, , OR, 2.44; 95% CI, 1.63-3.64, P = 0.001), TRUS biopsy Gleason score (7-10, OR, 2.50; 95% CI, 1.66-3.76, P = 0.001), postoperative Gleason score (OR, 4.01; 95% CI, 2.08-7.74, P = 0.001), clinical stage (≥ T3, OR, 1.77; 95% CI, 1.05-3.01, P = 0.032), pathological stage (≥ T3, OR, 3.24; 95% CI, 2.10-4.98, P = 0.001), and D' Amico classification (high, OR, 3.48; 95% CI, 2.31-5.23, P = 0.001) were associated with BCR, whereas, similar to the predictors of EPE, age (≥69 years), prostate volume, and the presence of hypoechoic lesion on TRUS were not associated with BCR ( Table 3) .
The multivariate analysis revealed that the preoperative serum PSA (adjusted OR, 1.04, 95% CI, 1.02-1.07, P = 0.001), PTV (adjusted OR, 1.02; 95% CI, 1.01-1.05, P = 0.046), perineural invasion (adjusted OR, 2.02; 95% CI, 1.15-3.57, P = 0.015), lymphovascular invasion (adjusted OR, 3.64; 95% CI, 1.53-8.66, P = 0.003), and TRUS biopsy Gleason score 7-10 (adjusted OR, 1.81; 95% CI, 1.01-2.97, P = 0.018) were associated with BCR ( Table 3) .
DISCUSSION
Identifying preoperative markers that predict disease recurrence and more aggressive PC after a radical prostatectomy is one of the main objectives of prostate oncology research. Several studies have reported that the preoperative serum PSA level, Gleason score, seminal vesicle invasion, surgical margin status, and pathological stage are independent predictors of disease recurrence after a radical prostatectomy. 10 Our results suggest that the preoperative serum testosterone and PTV also predict disease recurrence and progression after LRP. 14 found that patients with extra-prostatic disease had significantly lower preoperative serum testosterone than those with organ confined PCa and suggested that low preoperative serum testosterone predicted EPE. Furthermore, Kim et al. 7 found a significant difference in EPE between normal and hypogonadal groups. In our study, there was also a significant difference in EPE between the two groups. Furthermore, low preoperative serum testosterone was an independent predictor of EPE.
In terms of BCR, Yamamoto et al. 15 reported that low preoperative serum testosterone was associated with BCR, while Kim et al. 7 found that BCR was more frequent in patients with low preoperative testosterone. In line with their results, we also found an association between low preoperative serum testosterone and BCR. Countering this, however, Zhang et al. 16 reported that a low preoperative serum testosterone was not associated with BCR in patients who underwent a radical prostatectomy. Lane et al. 17 also demonstrated that a low preoperative total testosterone level was found to have a marginal association with a predominance of high-grade PCa at prostatectomy without an association with either the actual or predicted risk of disease progression. This discrepancy might be caused by the different proportion of locally advanced PCa in patients with low preoperative serum testosterone.
The mechanism involving preoperative serum testosterone, disease progression, and prognosis is not yet clear. Many hypotheses regarding the mechanism have been proposed, including changes secondary to the hormonal changes in chronic disease, 18 the inhibition of testosterone levels by high-grade tumors, 16 the central inhibition of the hypothalamic-pituitary axis, 19 the selection of poorly differentiated cancer cells due to low androgen levels, or purely a surrogate of other factors related to the pathological state. 14 Recently, several studies have suggested that testosterone therapy actually protects against PCa recurrence. In the largest series to date, Pastuszak et al. 20 evaluated 103 hypogonadal males who received testosterone therapy after radical prostatectomy and compared BCR with that in 49 eugonadal males. After a median 27.5-month follow-up, there were four BCRs (4%) in the testosterone therapy group versus eight (16%) in the nontestosterone therapy group. 20 This finding is supported by laboratory data demonstrating that androgens promote less aggressive phenotypes and inhibit dedifferentiation in some PCa cell lines. 11 The evidence includes the findings that activation of membrane androgen receptors induced the apoptotic regression of human PCa cells in vitro and in vivo, 21 androgens triggered the inhibition of cell proliferation at a higher concentration in LNCaP cells, 22 and androgens caused growth suppression and reversion of androgen-independent tumors to an androgen-stimulated phenotype. 23 Studies of the exact mechanism of the effects of low testosterone on prostate cancer are needed.
The ability of tumor volume to predict disease recurrence after radical prostatectomy remains controversial. Some investigators have reported that tumor volume is an independent predictor of disease recurrence. 2, 6, 24, 25 In practice, however, using the tumor volume as a predictive marker is difficult, because no uniform, standardized method of estimating the tumor volume has been accepted by uropathologists, although many investigators have proposed various accurate or practical methods. Maximum tumor diameter, 24 maximum tumor area, 26 tumor volume, 2 PTV, 6 and positive-block ratio 25 have all been suggested as significant, useful predictors of disease recurrence.
In this study, the tumor volume was calculated as the PTV, which was determined as the sum of all visually estimated tumor foci in 11 However, the decades-old beliefs regarding androgens and PCa have changed dramatically with recent evidence and new theoretical constructs. Males with high serum testosterone are not at increased risk of developing PCa, and low serum testosterone provides no protection against the development of PCa. 12, 13 every section. In addition, PTV was an independent predictor of BCR in the multivariate analysis. However, compared with other clinicopathological variables in our study, the preoperative serum PSA and lymphovascular invasion were much stronger predictors of BCR than PTV. Our results were consistent with those of previous studies.
Some investigators have failed to demonstrate the prognostic significance of tumor volume. 27 In those studies, contrary to our methodology, the tumor volume was calculated using the equation reported by D'Amico et al. 28 Even in those studies, however, tumor volume was uniformly associated with all other clinical and pathological variables. Therefore, further studies are necessary to validate tumor volume as an independent predictor of BCR after radical prostatectomy.
In addition, several studies have found that BCR was significantly associated with prostate volume. 4, 29 In those studies, males with smaller prostates were at a significantly higher risk of BCR. 4, 29 The reason for this remains unknown, although there are many potential explanations. First, it has been suggested that males with smaller prostates have lower testosterone levels, which has been associated with more aggressive PCa.
14 Second, tumors were detected earlier in males with larger prostates because of PSA-induced biopsies resulting from PSA elevation from an enlarged gland. 30 Third, a tumor within a small prostate has to migrate a shorter distance to escape the prostatic capsule. This is supported by Yadav et al. 31 who reported that a decreased prostate volume is a predictor of EPE.
Our study has a number of limitations. First, the number of patients for a common disease such as PC was not sufficiently large (n = 520). Probably due to this, there were some discrepancies in the results. Gleason score, clinical stage, and D' Amico classification which are previously known predictive factors of EPE were not significant in multivariate analysis. Larger cohort should be needed to elucidate these discrepancies. Second, the mean follow-up period was relatively short (median 19.1 months). Extending the follow-up period to 5 years might provide stronger evidence for our conclusions. Third, the visually estimated PTV possesses potential for under-or over-estimating the actual tumor volume. Interobserver variability exists. However, a simpler PTV might be sufficient for individual prognostication because accurately estimating the actual tumor volume might be of significant value for research purposes. Finally, the results of this study might be distorted by the distribution of surgical Gleason score 8-10 disease (23.8% of the population). Of the patients, 19% had biopsy Gleason scores ≥8, and 39.6% had high-risk disease preoperatively. A similar distribution has been reported in previous Asian studies and needs to be considered when interpreting the results.
CONCLUSION
In addition to previous predictors of PCa progression, such as the preoperative serum PSA and Gleason score, this study showed that the preoperative serum testosterone and PTV were helpful for predicting EPE and BCR after LRP. This information might help urologists to predict postoperative PCa progression and guide patient expectations and disease prognosis.
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